Back to INSMView Full Landscape
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
39 competitors in Cystic Fibrosis
ARCTARCT-032
VRTXTezacaftor/Ivacaftor
Phase 3VRTXELX/TEZ/IVA
Phase 3VRTXLUM/IVA
Phase 3VRTXTEZ/IVA
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMAPending
Arikayce
Arikayce is indicated for: treatment of Mycobacterium avium Complex (MAC) lung disease in adult patients who have persistent positive sputum cultures despite the use of medically appropriate first-line therapy Consideration should be given to official guidance on the appropriate use of antibacterial agents. Arikayce should be added to existing therapy and should not be used as monotherapy.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
